Feb 24, 2025
NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
Feb 04, 2025
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer